Kidney Cancer
Prostate Cancer
EAU Edu Platform on Bladder Cancer
Home
Articles
Article of the Month
Editorial
Videos
Webcasts
Education
E-courses
Webinars
ESOU Online
Clinical problems
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorial
Videos
Webcasts
Education
Terug
E-courses
Webinars
ESOU Online
Clinical problems
Guidelines
Events
Upcoming event
ASCO Annual Meeting 2022
Home
/
ASCO GU21
Back
Tag:
ASCO GU21
A phase Ib single-arm study of bintrafusp alfa
View
Optimal therapy is intravesical
View
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA)
View
SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy
View
A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE)
View
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
I agree
Read More